DLX6-AS1: A Long Non-coding RNA With Oncogenic Features

Soudeh Ghafouri-Fard1, Sajad Najafi2, Bashdar Mahmud Hussen3,4, Aryan R. Ganjo4, Mohammad Taheri5,6* and Mohammad Samadian7*

1Department of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran, 2Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran, 3Department of Pharmacognosy, College of Pharmacy, Hawler Medical University, Kurdistan Region, Erbil, Iraq, 4Center of Research and Strategic Studies, Lebanese French University, Erbil, Iraq, 5Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran, 6Institute of Human Genetics, Jena University Hospital, Jena, Germany, 7Skull Base Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Long non-coding RNAs (lncRNAs) are a heterogeneous group of ncRNAs with characteristic size of more than 200 nucleotides. An increasing number of lncRNAs have been found to be dysregulated in many human diseases particularly cancer. However, their role in carcinogenesis is not precisely understood. DLX6-AS1 is an lncRNAs which has been unveiled to be up-regulated in various number of cancers. In different cell studies, DLX6-AS1 has shown oncogenic role via promoting oncogenic phenotype of cancer cell lines. Increase in tumor cell proliferation, migration, invasion, and EMT while suppressing apoptosis in cancer cells are the effects of DLX6-AS1 in development and progression of cancer. In the majority of cell experiment, mediator miRNAs have been identified which are sponged and negatively regulated by DLX6-AS1, and they in turn regulate expression of a number of transcription factors, eventually affecting signaling pathways involved in carcinogenesis. These pathways form axes through which DLX6-AS1 promotes carcinogenicity of cancer cells. Xenograft animal studies, also have confirmed enhancing effect of DLX6-AS1 on tumor growth and metastasis. Clinical evaluations in cancerous patients have also shown increased expression of DLX6-AS1 in tumor tissues compared to healthy tissues. High DLX6-AS1 expression has shown positive association with advanced clinicopathological features in cancerous patients. Survival analyses have demonstrated correlation between high DLX6-AS1 expression and shorter survival. In cox regression analysis, DLX6-AS1 has been found as an independent prognostic factor for patients with various types of cancer.

Keywords: DLX6-AS1, non-coding RNA, lncRNA, cancer, miRNA

INTRODUCTION

In complex organisms, genome sequencing analyses have unveiled that just a small fraction of genome (e.g., 1–2% for mammals) encodes for protein via coding RNAs or messenger RNAs (mRNAs) that are located in the middle of central dogma making connection between DNA and corresponding protein. These protein-coding regions are those which have been described as genes for more than half a century in biology literature. However, the majority of large genomes i.e., more than 80% is transcribed to non-coding RNAs (ncRNAs) for which no corresponding protein have
been found, but a huge number of regulatory functions are recognized. Unlike the primary expectations which termed ncRNAs as “junk” DNA without biological importance, today it is clarified that they are involved in gene regulation at transcriptional and post-transcriptional levels, and through which they play critical roles in a vast number of biological processes such as imprinting, methylation, and silencing via several interactions with DNA, RNA, and proteins (Mattick, 2001). Based on size and function of transcripts, ncRNAs are categorized in several classes including microRNAs (miRNAs), small interfering RNAs (siRNAs), PIWI-interacting RNAs and long ncRNAs (lncRNAs). Transcripts of more than 200 nucleotide length are classified as lncRNAs which were primarily reported by Okazaki et al. in an analysis of mouse transcriptome in 2002 (Okazaki et al., 2002). RNA polymerase II is predominantly responsible for transcription of lncRNAs. They mainly endure capping, polyadenylation, splicing after transcription, and also trimethylation on histone 3 corresponding to lysine 4 (H3K4me3) (Losko et al., 2016; Bertone et al., 2004; Guttman et al., 2009). Thousands of heterogenous lncRNAs have been identified in multicellular organisms [60,000 encoding loci in human genome (Iyer et al., 2015)] showing tissues specificity which is also conserved during evolution (Necșulea et al., 2014) and acting as regulators of gene expression both in nucleus or cytoplasm (Fatica and Bozzoni, 2014) suggesting their involvement in specific biologic processes. Several databases have been created to store and provide access to these databases. Examples of these databases are TRlnc for regulatory lncRNAs in humans (Li et al., 2020a), IncRNAASN1 and 2 for single nucleotide polymorphisms (SNPs) of human and mouse lncRNAs (Gong et al., 2014; Miao et al., 2017), LncRNA2Target v2.0 for target genes of lncRNAs (Cheng et al., 2018), CRISPRlnc for validated single guide RNAs (sgRNAs) used in clustered regularly interspaced short palindromic repeats (CRISPR)-associated protein number 9 (Cas9) gene editing technology for lncRNAs (Chen et al., 2018) and clusLnc2Cancer for effective lncRNAs in human cancers (Ning et al., 2015). They act in cis and trans modes by gathering and localizing transcription factors to a locus. Gene expression regulation at several levels including transcription, translation and splicing, epigenetic regulation in X-chromosome inactivation or dosage compensation, genomic imprinting, involvement in developmental and differential processes, neurogenesis, regulation of cell cycle, and cell transportation are among the fundamental roles which have been recognized for lncRNAs (Mattick, 2009; Wilusz et al., 2009; Wu et al., 2013; Dey et al., 2014; Fatica and Bozzoni, 2014). Accordingly, an increasing number of lncRNAs have been associated with various types of human diseases. Dysregulation in expression levels or mutation of lncRNAs are found to play role in the pathogenesis of diseases like age-related diseases, cardiovascular diseases (Uchida and Dimmel, 2015), kidney and liver diseases (Takahashi et al., 2014; Ignarski et al., 2019), ophthalmologic diseases (Wawrzyniak et al., 2018), neurodegenerative and other diseases affecting central nervous system (CNS) (Pastori and Wahlstedt, 2012; Wan et al., 2017), and particularly various types of cancer. Mediation of a number of cancer-associated processes like cell cycle regulation, epigenetic regulation, and involvement in signaling pathways and hormone-related pathways indicate potential roles of lncRNAs act as contributors in the development and progression of cancer (Sahu et al., 2015). MALAT1, HOTAIR, H19, HOTTIP, ANRIL, and NEAT1 are among the most famous lncRNAs which have been mostly studied in many types of cancer exhibiting dysregulation in cancer cells, tissues and body fluids of affected patients. In this review, we aim to have an overview of studies which have assessed tumorigenic effects of the lncRNA distal-less homeobox 6 antisense RNA 1 (DLX6-AS1) in three levels of cell, animal, and human studies. In humans, DLX6-AS1 gene is located on chromosome 7q21.3, primarily identified by Feng et al. (2006) to promote DLX5/6 function in trans mode. This lncRNA has been found to be up-regulated in a growing number of different types of cancerous tissues compared to normal tissues. Promoting carcinogenesis via increasing tumor cell proliferation, migration, and invasion through enhancing Epithelial–Mesenchymal Transition (EMT) along with suppression of apoptosis and chemosensitivity have been shown in cell studies of DLX6-AS1 overexpression. Enhanced tumor growth and metastasis has confirmed tumorigenic potentials of DLX6-AS1 in animal studies. Correlation between high DLX6-AS1 expression and advanced clinicopathological features and also poor prognosis and survival in cancerous patients has suggested DLX6-AS1 not only as a diagnostic and prognostic biomarker but also as a therapeutic target.

**Functional Effects of DLX6-AS1 on Cell Proliferation, Apoptosis and Migration**

Cancer cell lines have been used to evaluate function of DLX6-AS1 in cell cycle progression, cell proliferation and apoptosis. Moreover, high throughput RNA sequencing and also confirmation via quantitative real-time polymerase chain reaction (qRT-PCR) analyses have facilitated identification of differentially expressed lncRNAs in cancer cell lines compared to controls. *In vitro* experiments have shown significant increase in expression levels of DLX6-AS1 in cancer cell lines. In different cell experiment, it has been demonstrated that DLX6-AS1 overexpression promotes tumor cell proliferation, migration, and invasion, while suppressing apoptosis. In cell counting, colony formation, and 5-Bromo-2-deoxyUridine (BrdU) assays, decreased proliferation of cancer cells is reported for DLX6-AS1 knockdown. Wound healing, Matrigel and Transwell assays for assessment tumor cell migration and invasion show suppressed metastatic capability of cancerous cells under DLX6-AS1 silencing. Flowcytometry also demonstrated cell cycle arrest in treated cancer cells. Furthermore, decreased cell viability and elevated apoptosis in 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT), flowcytometry, and apoptotic marker assays have unveiled increased apoptosis in DLX6-AS1-silenced cancer cells. In hepatocellular carcinoma (HCC), DLX6-AS1 has been shown to be highly expressed in human HCC cell lines versus normal liver cells, while miR-513c as its downstream microRNA...
exhibited down-regulation indicating DLX6-AS1 acts as sponge for this miRNA (Liu et al., 2020a). Cullin4A (Cul4A) was also known as target gene of miR-513c which showed increase in expression level following DLX6-AS1 up-regulation. In other words, DLX6-AS1 elevated Cul4A expression by binding to and sponging miR-513c. Cul4A, itself positively regulated activity of annexin A10 (ANXA10). DLX6-AS1 silencing using specific short hairpin RNA (shRNA) repressed cell viability, invasion, and migration of HCC cells. Also, Cul4A knockdown was shown to inhibit tumorigenic effects of HCC cells via inhibition of ANXA10 degradation through ubiquitin-associated pathway. The results showed that DLX6-AS1 exerts its tumorigenic role via miR-513c/Cul4A/ANXA10 axis. In a distinct study (Zhang et al., 2017), DLX6-AS1 was shown to exert same tumorigenic roles in HCC cells via miR-203a/MMP-2 axis.

In other experiments, DLX6-AS1 has been shown to sponge many other miRNAs and affect transcription factors, genes or signaling pathways which eventually promotes malignant phenotypes. miRNAs which are mainly negatively regulated by up-stream DLX6-AS1 exhibit down-regulation in cancer tissues and cells, and their overexpression reverse the malignant phenotypes of DLX6-AS1 in cancer cell lines. Downstream factors demonstrate expression changes consistent with DLX6-AS1. Overexpression of these factors drives same influences with DLX6-AS1 overexpression. In a study in ovarian cancer (Kong and Zhang, 2020), miR-195-5p was shown to be down-regulated.
# TABLE 1 | an overview to the oncogenic influences of DLX6-AS1 in cell studies of different types of cancer.

| Cancer type | Targets/Regulators and signaling pathways | Assessed cell lines | Function | References |
|-------------|------------------------------------------|---------------------|----------|------------|
| HCC         | miR-513c/Cu4A/ANKA10 axis, miR-203a/MMP-2 axis | Hep3B, HepG2, Huh7, PLC/PRF/5, and THLE-3, Hep3B, MHCC97L, HCCLM3, HepG2, Huh7, and LO2 | Δ DLX6-AS1: ↑ tumor cell viability, ↑ invasion, and ↑ migration | Liu et al. (2020a) |
| Pancreas    | miR-181b/2EB2 axis, miR-497-5p/Fzd4/Fzd6/ Wnt/β-catenin axis | CAPAN-1, BxPC-3, SW 1990, Panc-1, and HPDE6-C7, Panc-1, AsPC-1, Bxpc-3, Capan-1, CFPAC-1, and Mia PaCa-2 | Δ DLX6-AS1: ↑ tumor cell proliferation, ↑ invasion, and ↑ migration | Zhao et al. (2017) |
| Liver       | miR-424-5p/WEE1 axis | MHCC97L, HCCLM3, SK-HEP-1, Hep3B, Huh7, and HEK293T | ↑↑ DLX6-AS1: ↑↑ cell cycle arrest at G1/S phase, ↑↑ cell proliferation and colony formation, and ↑↑ cell migration | Zhang et al. (2018) |
| Kidney (renal cell carcinoma; RCC) | miR-203a/MMP-2/PTEN axis | A498, ACHN, Caki-1, Caki-2, 786-O, and HK-2 | Δ DLX6-AS1: ↓ tumor cell proliferation, ↓ apoptosis, and ↓ cell cycle arrest | Li et al. (2020b) |
| Neuroblastoma | miR-513c-5p/PLK4 axis, miR-506-5p/STAT2 axis | SK-N-SH and LAN-6, SK-N-AS, IMR-32, and SH-SY5Y | Δ DLX6-AS1: ↓ tumor cell proliferation, ↓ migration, and ↓ invasion | Zeng et al. (2017) |
| Gloma       | miR-199a CaSki, ME-180, C-33A, SiHa, HeLa, and NC104 | U251, T98G, U87MG, SHG44, and HNA | Δ DLX6-AS1: ↑ tumor cell proliferation, and ↑ invasion | Zhao et al. (2019a) |
| Osteosarcoma | miR-129-5p/DLK1 axis, miR-641/HOXA9 axis | MG63 and U2OS, Saos-2, MG-63, U2OS and hFOB | Δ DLX6-AS1: ↓ number and size of tumor spheres, and ↓ colony formation and colony cell cycle arrest at G1/S phase | Zhao and Xu, (2020) |
| Endometria  | DLX6 | HEC-1-B, HHUA, HEC-1-A, RL-952, and HEC-251 | Δ DLX6-AS1: ↑ tumor cell proliferation, ↓ inflammation, and ↓ apoptosis | Zhao et al. (2019b) |
| Cervix      | miR-16-5p/ARPP19 Axis, miR-199a | SiHa, HeLa, C-33A, CaSiKi, and End1/ E6E7, CaSiKi, ME-180, C-33A, SiHa, HeLa, and NC104 | Δ DLX6-AS1: ↑ tumor cell proliferation, ↓ migration, ↓ EMT and ↓ apoptosis | Xie et al. (2020) |
| Breast (triple-negative; TNBC) | miR-199b-5p/paxillin axis | MDA-MB-231, MDA-MB-468, BT-474, MCF-7, E6E7, and MCF-10A | Δ DLX6-AS1: ↑ tumor cell proliferation, ↑ migration, ↓ invasion, and ↓ apoptosis | Zhao et al. (2019) |
| Ovaries     | miR-196-5p/FOH2L2 axis, Notch | SKOV3, A2780, IOSE80, and 293 T | SKOV3, IOSE80, HEY, SKOV3, and OVCAR-3 | Δ DLX6-AS1: ↓ tumor cell proliferation, ↓ migration, ↓ invasion, and ↓ apoptosis | Kong and Zhang, (2020) |
| Bladder     | miR-195-5p/VEGFA, Wnt/β-catenin axis | T24, RT4, 5637, J82, SW780, and SV-HUC-1, T24, and SV-HUC-1 | Δ DLX6-AS1: ↓ tumor cell proliferation, ↓ migration, ↓ invasion, and ↓ apoptosis | Zhao et al. (2020a) |

(Continued on following page)
TABLE 1 | (Continued) an overview to the oncogenic influences of DLX6-AS1 in cell studies of different types of cancer.

| Cancer type | Targets/Regulators and signaling pathways | Assessed cell lines | Function | References |
|-------------|------------------------------------------|---------------------|----------|------------|
| Colorectal  | miR-223/HSP90B1 axis                     | T24, SW780, and SV-HUC-1 | Δ DLX6-AS1: ↑ tumor cell proliferation, and ↓ invasion | Fang et al. (2019) |
|             | miR-29a/PI3K pathway                     | DLD-1, HCT-116, HT-29, SW480, SW600, and NOMC460 | Δ DLX6-AS1: ↑ tumor cell proliferation, ↓ migration, ↓ invasion, and ↑ cell cycle arrest | Kong et al. (2020) |
|             | miR-199a-5p/HIF-1 axis                   | S18, S26, CNE-1, CNE-2, HONE-1, 5-8F, and NPE69 | Δ DLX6-AS1: ↓ tumor cell proliferation, ↓ invasion, and ↑ cell cycle arrest | Yang et al. (2020) |
| Stomach     | miR-195-5p/EZH2 Axis                     | HGC-27, SGC7901, MGC803, and GES-1 | Δ DLX6-AS1: ↓ tumor cell proliferation, ↑ apoptosis, and caused glucose metabolism impairment | Qian et al. (2021) |
|             | FUS/FOXO71 axis                          | AGS, HGC-27, SGC-7901, BGC-823, and GES-1 | Δ DLX6-AS1: ↑ tumor cell proliferation, ↓ migration, and ↓ EMT | Wu et al. (2020) |
|             | miR-376c/LIM domain protein 2             | MGC-803, HGC-27, MKN-7, MKN-28, MKN-45, AGS, SGC-7901, and GES-1 | Δ DLX6-AS1: ↓ tumor cell proliferation, ↓ invasion, ↓ migration, and ↓ EMT | Liang et al. (2020) |
|             | --                                       | EC109, KYSE30, and Het-1A | Δ DLX6-AS1: ↑ tumor cell proliferation, ↓ migration, ↓ invasion, and ↓ cell cycle arrest | Lei et al. (2019) |
| Larynx      | miR-195-5p/PI3K/mTOR pathway             | HEp-2 and Tu-177 | Δ DLX6-AS1: ↑ tumor cell proliferation via decrease in mitochondrial radical oxygen species | Liu et al. (2020b) |
|             | miR-199a-5p/HIF-1 axis                   | S18, S26, CNE-1, CNE-2, HONE-1, 5-8F, and NPE69 | Δ DLX6-AS1: ↑ tumor cell proliferation, ↓ invasion, and ↑ cell cycle arrest | Yang et al. (2019b) |
| Nasopharynx | miR-199a-5p/HIF-1a axis                  | S18, S26, CNE-1, CNE-2, HONE-1, 5-8F, and NPE69 | Δ DLX6-AS1: ↑ tumor cell proliferation, ↓ migration, and ↓ invasion | Yang et al. (2020) |
| Esophagus   | --                                       | EC109, KYSE30, and Het-1A | Δ DLX6-AS1: ↑ tumor cell proliferation, ↓ migration, ↓ invasion, and ↓ EMT | Zhang et al. (2019c) |
| Lung (NSCLC)| miR-204-5p/OCT1 axis                     | HGC27, BGC-823, SGC7901, AGS, and GES-1 | Δ DLX6-AS1: ↑ tumor cell proliferation, ↓ invasion, and ↓ cell cycle arrest | Fu et al. (2019) |
|             | miR-144/PRR11 axis                       | H1975 and A549 | Δ DLX6-AS1: ↑ tumor cell proliferation, ↓ migration, ↓ invasion, and ↓ apoptosis | Huang et al. (2019) |
|             | miR27b3p/PDK1 axis                       | CALLU3, CALLU6, A549, H1299, and HBE | Δ DLX6-AS1: ↓ proliferation, ↓ migration, and ↓ invasion | Sun et al. (2019) |
| Ewing’s sarcoma| miR-124-3p/CDK4 axis                    | SK-ES-1, A673, RD-ES, and mesenchymal stem cells (MSCs) | Δ DLX6-AS1: ↓ tumor cell proliferation, and ↓ apoptosis | Lei et al. (2019) |

Δ: knockdown or silencing, ↓: decrease or repression, ↑: increase or stimulation, ↑↑: overexpression, CSCs: cancer stem cells.

In cancer tissues and was identified as target of up-regulated DLX6-AS1. While DLX6-AS1 promoted cell proliferation, migration, and invasion in tumor cell lines, miR-195-5p overexpression reversed malignant phenotypes. Four and a half LIM domains protein 2 (FHL2) which is known to play role in development and progression of different types of cancer via activation of androgen receptor (AR or NR3C4), Wnt/β-catenin pathway or several genes was demonstrated as target of miR-195-5p. FHL2 overexpression exhibited same results on malignant phenotypes of cancer cells. In other words, DLX6-AS1 exerted its tumorigenic effects in ovarian cancer cells via miR-195-5p/FHL2 signaling axis. In bladder cancer, miR-195-5p as target of DLX6-AS1 was shown to down-regulate the vascular endothelial growth factor A (VEGFA) and consequently inhibit malignancy phenotype in cancer cells, while miR-195-5p inhibition returned the DLX6-AS1 tumorigenic effects (Zhao et al., 2020a).

Furthermore, DLX6-AS1 has been shown to up-regulated DLK1, a regulator of cell differentiation and prognostic factor for several cancers, through sponging miR-129-5p which in turn triggers Wnt signaling, and eventually promotes stemness in osteosarcoma cell lines (Zhang et al., 2018). PI3KAKT/mTOR signaling pathway is another critical tumorigenic pathway which is known to be activated by DLX6-AS1, promoting malignant phenotype of colorectal cancer cells (Zhang et al., 2019a).

Overall, it is demonstrated that DLX6-AS1 acts as an oncogenic IncRNA enhancing malignant phenotype of several cancer cells (Figure 1).

DLX6-AS1 is oncogenic IncRNA has been found to be up-regulated in a growing number of different types of cancerous tissues compared to normal tissues. Promoting carcinogenesis via increasing tumor cell proliferation, migration, and invasion through enhancing Epithelial–Mesenchymal Transition (EMT). miRNAs have been identified which are negatively regulated by DLX6-AS1, and they regulate expression of a number of transcription factors, eventually affecting signaling pathways involved in carcinogenesis.

Table 1 shows the findings of the studies conducted on DLX6-AS1 oncogenic role in various cancer cell lines.
Experiments in animal models have confirmed oncogenic role of DLX6-AS1. It is expected that DLX6-AS1 overexpression or silencing increases or suppresses malignant features of cancer cells in xenograft models, respectively. To examine this claim, treated cells; either overexpressing or with silenced for DLX6-AS1; have been injected to the animals; mainly BALB/c nude mice, and then tumor size or volume, and metastasis in expected organ have been checked at certain intervals. Changes in chemosensitivity have also been assessed occasionally. Decreased tumor growth and metastasis, and also chemoresistance have been reported under DLX6-AS1 knockdown conditions in animal studies. Opposite findings have been reported when DLX6-AS1 was overexpressed in injected cancer cells to the nude mice. Taken together, these findings demonstrate oncogenic role of DLX6-AS1 in tumor progression and metastasis in animal studies are consistent with the results of cell studies (Table 2).

### TABLE 2 | Effects of DLX6-AS1 on tumor growth and metastasis in animal studies.  

| Cancer type | Animal models | Function | References |
|-------------|---------------|----------|------------|
| HCC         | BALB/c nude mice | ∆ DLX6-AS1: ↓ tumor growth | Liu et al. (2020a) |
|             | BALB/c nude mice | ∆ DLX6-AS1: ↓ tumor growth | Zhang et al. (2017) |
| Pancreas    | BALB/c athymic nude mice | ∆ DLX6-AS1: ↓ tumor growth | An et al. (2018) |
|             | BALB/c athymic nude mice | ∆ DLX6-AS1: ↓ tumor growth, and ↓ metastasis | Yang et al. (2019a) |
| Prostate    | BALB/c nude mice | ∆ DLX6-AS1: ↓ tumor growth | Zhu et al. (2021) |
|             | SCID mice | ∆ DLX6-AS1: ↑ tumor growth | Zhao et al. (2020b) |
|             | BALB/c nude mice | ∆ DLX6-AS1: ↓ tumor growth | Jia et al. (2020) |
|             | BALB/c nude mice | ∆ DLX6-AS1: ↓ tumor growth | Han et al. (2020) |
|             | BALB/c nude mice | ∆ DLX6-AS1: ↓ tumor growth | Li et al. (2020b) |
|             | BALB/c nude mice | ∆ DLX6-AS1: ↓ tumor growth | Li et al. (2019b) |
| Neuroblastoma | Male nude mice | ∆ DLX6-AS1: ↓ tumor growth | Zhang et al. (2019b) |
| Gloma       | 32 healthy nude mice | ∆ DLX6-AS1: ↓ tumor growth | Zhao and Xu, (2020) |
| Endometria  | 32 healthy nude mice | ∆ DLX6-AS1: ↓ tumor growth | Xie et al. (2020) |
| Cervix      | BALB/c nude mice | ∆ DLX6-AS1: ↓ tumor growth | Du et al. (2020) |
| Breast (TNBC) | BALB/c nude mice | ∆ DLX6-AS1: ↓ tumor growth, and ↓ chemoresistance to cisplatin | Kong and Zhang, (2020) |
| Ovaries     | BALB/c nude mice | ∆ DLX6-AS1: ↓ tumor growth | Zhao et al. (2020a) |
| Bladder     | BALB/c nude mice | ∆ DLX6-AS1: ↓ tumor growth | Guo et al. (2019) |
| Larynx      | BALB/c nude mice | ∆ DLX6-AS1: ↓ tumor growth | Liu et al. (2020b) |
| Stomach     | BALB/c nude mice | ∆ DLX6-AS1: ↓ tumor growth | Qian et al. (2021) |
| Osteosarcoma | BALB/c nude mice | ∆ DLX6-AS1: ↓ tumor growth | Zhang et al. (2018) |
| Lung (NSCLC)| BALB/c nude mice | ∆ DLX6-AS1: ↓ tumor growth | Huang et al. (2019) |
| Colorectal  | Female nude mice | ∆ DLX6-AS1: ↓ tumor growth | Sun et al. (2019) |
| Liver       | NOD-SCID mice | ∆ DLX6-AS1: ↓ tumor growth | Zhang et al. (2019a) |
| Kidney (RCC)| BALB/c nude mice | ∆ DLX6-AS1: ↓ tumor growth | Wu et al. (2019) |

## IMPACT OF DLX6-AS1 ON ENHANCEMENT OF TUMOR GROWTH

Experiments in animal models have confirmed oncogenic role of DLX6-AS1. It is expected that DLX6-AS1 overexpression or silencing increases or suppresses malignant features of cancer cells in xenograft models, respectively. To examine this claim, treated cells; either overexpressing or with silenced for DLX6-AS1; have been injected to the animals; mainly BALB/c nude mice, and then tumor size or volume, and metastasis in expected organ have been checked at certain intervals. Changes in chemosensitivity have also been assessed occasionally. Decreased tumor growth and metastasis, and also chemoresistance have been reported under DLX6-AS1 knockdown conditions in animal studies. Opposite findings have been reported when DLX6-AS1 was overexpressed in injected cancer cells to the nude mice. Taken together, these findings demonstrate oncogenic role of DLX6-AS1 in tumor progression and metastasis in animal studies are consistent with the results of cell studies (Table 2).

## IMPACT OF DLX6-AS1 ON SURVIVAL OF PATIENTS WITH DIFFERENT TYPES OF CANCERS

Cancerous tissues resected from patients have shown significantly increased expression of DLX6-AS1 compared to matched normal adjacent tissues (NATs) and healthy people in microarray analysis and qRT-PCR. In non-small cell lung cancer (NSCLC), DLX6-AS1 high expression levels were found to be positively associated with advanced clinicopathological features including higher disease stage, tumor metastasis to lymph nodes and also weak differentiation of cancer cells in patients (Zhang et al., 2019c). Also, Guo et al. (2019) demonstrated high DLX6-AS1 expression in bladder cancer patients with advanced TNM stage, positive lymph node and distant metastases. Survival analysis via Kaplan-Meier curve has shown association between high DLX6-AS1 expression and shorter overall survival (OS), and/or disease-free survival (DFS) in several types of cancer like HCC (Liu et al., 2020a; Zhang et al., 2017), gastric cancer (Qian et al., 2021; Fu et al., 2019), glioma...
TABLE 3 | Clinical prognostic importance of DLX6-AS1 in human cancers.

| Cancer type | Clinical samples | Expression change in tumor tissues compared to normal tissues | Kaplan-Meier analysis | Multivariate cox regression | References |
|-------------|------------------|-------------------------------------------------------------|-----------------------|----------------------------|------------|
| HCC         | 85 cancerous patients and matched NATs | Up | Patients with high DLX6-AS1 expression had poor OS compared to those with lower levels | -- | Liu et al. (2020a) |
|             | 60 cancerous patients and matched NATs | Up | High DLX6-AS1 expression levels were correlated with poor OS in HCC patients compared to low levels | -- | Zhang et al. (2017) |
| Larynx      | 43 cancerous patients and matched NATs | Up | Patients with high DLX6-AS1 expression had shorter OS compared to those with lower levels | -- | Liu et al. (2020b) |
| Stomach     | 60 cancerous tissues and 28 NATs | Up | High DLX6-AS1 expression levels were associated with poor OS. | DLX6-AS1 expression is an independent predictor of poor prognosis | Qian et al. (2021) |
|             | 375 cancerous tissues and 32 NATs | Up | -- | -- | Liang et al. (2020) |
|             | 62 cancerous tissues and matched NATs | Up | High DLX6-AS1 expression levels correlated with shorter survival in gastric cancer patients compared to those with low levels | -- | Fu et al. (2019) |
| Gloma       | 36 cancerous tissues and matched NATs | Up | Patients with high DLX6-AS1 expression levels exhibited shorter OS compared to those with low levels | -- | Zhang et al. (2019b) |
| Osteosarcoma| 80 cancerous tissues and matched NATs | Up | High DLX6-AS1 expression levels were correlated with shorter OS in osteosarcoma patients compared to low levels | DLX6-AS1 expression level is an independent prognostic factor | Zhang et al. (2018) |
| Breast      | 45 cancerous tissues and matched NATs | Up | High DLX6-AS1 expression levels were correlated with shorter OS in osteosarcoma patients compared to low levels | -- | Zhao et al. (2019) |
| Pancreas    | 60 cancerous tissues and matched NATs | Up | Patients with low DLX6-AS1 expression levels exhibited higher survival rate compared to those with high levels | -- | Yang et al. (2019a) |
|             | 84 cancerous tissues and matched NATs | Up | -- | -- | An et al. (2018) |
| Prostate    | 20 cancerous tissues and matched NATs | Up | -- | -- | Zhu et al. (2021) |
|             | 32 cancerous patients and 28 patients with benign prostate hyperplasia | Up | -- | -- | Zhao et al. (2020b) |
| Neuroblastoma| 20 cancerous tissues and matched NATs | Up | -- | -- | Jia et al. (2020) |
|             | 31 cancerous tissues and matched NATs | Up | -- | -- | Han et al. (2020) |
|             | 70 cancerous tissues and matched NATs | Up | High DLX6-AS1 expression levels were significantly associated with shorter OS in neuroblastoma patients compared to those with low levels | -- | Li et al. (2020b) |
|             | 88 cancerous tissues and matched NATs | Up | High DLX6-AS1 expression levels were correlated with shorter OS in neuroblastoma patients compared to those with low levels | -- | Li et al. (2019b) |
| Endometria  | 78 cancerous tissues and matched NATs | Up | -- | -- | Zhao and Xu (2020) |
| Breast (TNBC)| 47 cancerous tissues and matched NATs | Up | -- | -- | Du et al. (2020) |

(Continued on following page)
(Zhang et al., 2019b), breast cancer (Zhao et al., 2019), and several others (Table 3). Competitive endogenous RNA (ceRNA) network analysis has demonstrated reliability of DLX6-AS1 along with three other lncRNAs and two more miRNAs in a signature as prognostic biomarkers in HCC patients (Long et al., 2019). Ding et al. (2021) showed serum exosomal levels of DLX6-AS1 can act as a prognostic biomarker in cervical cancer patients. Also, multivariate cox regression has shown that DLX6-AS1 is an independent prognostic factor for survival in a number of cancers such as gastric cancer (Qian et al., 2021), osteosarcoma (Zhang et al., 2018), and ovarian cancer (Zhao and Liu, 2019). Furthermore, a value of 0.795 for area under curve (AUC) in receiver operating characteristic (ROC) curve has shown acceptable efficiency of DLX6-AS1 in diagnosis of glioma (Zhang et al., 2019b). Taken together, according to the clinical data, DLX6-AS1 is suggested as a potential prognostic biomarker for different types of human cancer and a putative factor to manage cancerous patients.

### DISCUSSION

LncRNAs are a heterogeneous group of ncRNAs with characteristic size of more than 200 nucleotides. An increasing number of lncRNAs have been found to be dysregulated in many human diseases particularly cancer. However, their role in

| Cancer type | Clinical samples | Expression change in tumor tissues compared to normal tissues | Kaplan-Meier analysis | Multivariate cox regression | References |
|-------------|------------------|---------------------------------------------------------------|-----------------------|-----------------------------|------------|
| Ovaries     | 50 cancerous tissues and matched NATs | Up | -- | DLX6-AS1 expression is an independent prognostic factor for survival in ovarian cancer patients | Kong and Zhang, (2020) Zhao and Liu, (2019) |
|             | 128 cancerous tissues and matched NATs | Up | -- | Patients with high DLX6-AS1 expression levels had shorter OS and DFS compared to those with low levels |  |
| Bladder     | 60 cancerous tissues and matched NATs | Up | -- | -- | Zhao et al. (2020a) Guo et al. (2019) |
|             | 54 cancerous tissues and matched NATs | Up | -- | -- |  |
| Colorectal  | 76 cancerous tissues and matched NATs | Up | -- | -- | Kong et al. (2020) Zhang et al. (2019a) |
|             | 60 cancerous tissues and matched NATs | Up | -- | -- |  |
| Larynx (LSCC) | 23 cancerous tissues and matched NATs | Up | -- | -- | Yang et al. (2019b) |
| Osteosarcoma | 40 cancerous tissues and matched NATs | Up | -- | -- | Zhang et al. (2019b) |
| Lung (NSCLC) | 48 cancerous tissues and matched NATs | Up | -- | -- | Huang et al. (2019) Sun et al. (2019) |
|             | 51 cancerous tissues and matched NATs | Up | -- | -- |  |
| Nasopharynx | 72 cancerous tissues and matched NATs | Up | -- | -- | Yang et al. (2020) |
| Esophagus   | 73 cancerous tissues and matched NATs | Up | -- | -- | Zhang et al. (2019c) |
| Liver       | 30 cancerous tissues and matched NATs | Up | -- | -- | Li et al. (2019a) |
| Cervix      | 78 cancerous tissues and matched NATs | Up | -- | -- | Long et al. (2019) |
| Kidney (RCC) | 15 cancerous tissues and matched NATs | Up | -- | -- | Zeng et al. (2017) |
| Ewing’s sarcoma | 20 cancerous tissues and matched NATs | Up | -- | -- | Lei et al. (2019) |

TABLE 3 (Continued) Clinical prognostic importance of DLX6-AS1 in human cancers.
carcinogenesis is not precisely understood. DLX6-AS1 is an IncRNAs which has been unveiled to be up-regulated in a number of various cancers. In different cell studies, DLX6-AS1 has shown oncogenic role via promoting oncogenic phenotype of cancer cell lines. Increase in tumor cell proliferation, migration, invasion, and EMT while suppressing apoptosis in cancer cells are the effects of DLX6-AS1 in the development and progression of cancer. Silencing experiments using specific shRNA against DLX6-AS1 have shown suppression of tumorigenic potential. Similar pattern of expression in different types of cancer originated from various tissues not only reveals its universal function in the tumorigenesis, but also emphasizes the suitability of therapeutic modalities against this IncRNA for a wide range of human malignancies.

In the majority of cell experiments, mediator miRNAs have been identified which are negatively regulated by DLX6-AS1, and they regulate expression of a number of transcription factors, eventually affecting signaling pathways involved in carcinogenesis. These pathways form axes through which DLX6-AS1 regulates transcription factors, and/or signaling pathways eventually promotes carcinogenicity of cancer cells. Identification of functional routes of DLX6-AS1 effects in the carcinogenesis is an important step toward design of targeted therapies in cancer. It is also important to mention that these therapies should not affect pathways with crucial roles in the physiological features of normal cells.

Xenograft animal studies also have confirmed enhancing effect of DLX6-AS1 on tumor growth and metastasis. Clinical evaluations in cancerous patients have shown increased expression of DLX6-AS1 in tumor tissues compared to healthy tissues. High DLX6-AS1 expression has shown positive association with advanced clinicopathological features in cancerous patients. Survival analyses have demonstrated correlation between high DLX6-AS1 expression and shorter survival. In Cox regression analysis, DLX6-AS1 has been suggested as an independent prognostic factor for patients with various types of cancer.

Animal and cell line studies have confirmed that therapeutic modalities targeting DLX6-AS1 can effectively reduce tumorigenic potential of malignant cells, induce their apoptosis and diminish tumor size and burden. However, the efficacy and safety of these methods have not been evaluated in the clinical settings.

Taken together, these findings demonstrate carcinogenic role of DLX6-AS1 in the development and progression of different human cancers suggesting diagnostic and prognostic potentials of DLX6-AS1 in human cancers. Known role of up-regulated DLX6-AS1 in cancer tissues and clinical samples also suggest therapeutic potentials in finding treatments for different types of cancer via targeting DLX6-AS1. Further studies are required to utilize diagnostic, prognostic, and therapeutic potentials of DLX6-AS1 in clinical settings. Moreover, measurement of DLX6-AS1 levels in biofluids is an important step towards identification of non-invasive routes for diagnostic purposes.

AUTHOR CONTRIBUTIONS

MT and SGF wrote the draft and revised it. SN and MS collected the data and designed the figures and tables. All the authors read and approved the submitted version.

REFERENCES

An, Y., Chen, X.-m., Yang, Y., Mo, F., Jiang, Y., Sun, D.-l., et al. (2018). LncRNA DLX6-AS1 Promoted Cancer Cell Proliferation and Invasion by Attenuating the Endogenous Function of miR-181b in Pancreatic Cancer. Cancer Cell Int 18 (1), 143. doi:10.1186/s12935-018-0643-7

Bertone, P., Stolc, V., Royce, T. E., Rozowsky, J. S., Urban, A. E., Zhu, X., et al. (2004). Global Identification of Human Transcribed Sequences with Genome Tiling Arrays. Science 306 (5705), 2242–2246. doi:10.1126/science.1103388

Chen, W., Zhang, G., Li, J., Zhang, X., Huang, S., Xiang, S., et al. (2018). CRISPRiLin: a Manually Curated Database of Validated sgRNAs for IncRNAs. Nucleic Acids Res. 47 (D1), D63–D68. doi:10.1093/nar/gky904

Cheng, L., Wang, P., Tian, R., Wang, S., Guo, Q., Luo, M., et al. (2018). LncRNA2Target v2.0: a Comprehensive Database for Target Genes of IncRNAs in Human and Mouse. Nucleic Acids Res. 47 (D1), D140–D144. doi:10.1093/nar/gky1051

Dey, B. K., Mueller, A. C., and Dutta, A. (2014). Long Non-coding RNAs as Emerging Regulators of Differentiation, Development, and Disease. Transcription 5 (4), e94014. doi:10.4161/trans.21542722.2014.944014

Ding, X. Z., Zhang, S. Q., Deng, X. L., and Qiang, J. H. (2021). Serum Exosomal DLX6-AS1 Promoted Cancer Cell Proliferation and Invasion by Attenuating miR-223-Hsp90b1 axis. Cell Cycle 18 (23), 3288–3299. doi:10.1080/15384101.2019.1673633

Fatica, A., and Bozzoni, I. (2014). Long Non-coding RNAs: New Players in Cell Differentiation and Development. Nat. Rev. Genet. 15 (1), 7–21. doi:10.1038/nrg3606

Feng, J., Bi, C., Clark, B. S., Mady, R., Shah, P., and Kohtz, J. D. (2006). The Evf-2 Noncoding RNA Is Transcribed from the Dlx-5/6 Ultraconserved Region and Functions as a Dlx-2 Transcriptional Coactivator. Genes Dev. 20 (11), 1470–1484. doi:10.1101/gad.141606

Fu, X., Tian, Y., Kuang, W., Wen, S., and Guo, W. (2019). Long Non-coding RNA DLX6-AS1 Silencing Inhibits Malignant Phenotypes of Gastric Cancer Cells. Exp. Ther. Med. 17 (6), 4715–4722. doi:10.3892/etm.2019.7521

Gong, J., Liu, W., Zhang, J., Miao, X., and Guo, A.-Y. (2014). lncRNASNP: a Database of SNPs in IncRNAs and Their Potential Functions in Human and Mouse. Nucleic Acids Res. 43 (D1), D181–D186. doi:10.1093/nar/gku1000

Guo, J., Chen, Z., Jiang, H., Yu, Z., Peng, J., Xie, J., et al. (2019). The IncRNA DLX6-AS1 Promoted Cell Proliferation, Invasion, Migration and Epithelial-To-Mesenchymal Transition in Bladder Cancer via Modulating Wnt/β-Catenin Signaling Pathway. Cancer Cell Int 19, 312. doi:10.1186/s12935-019-1010-z

Guttman, M., Amit, I., Garber, M., French, C., Lin, M. F., Feldser, D., et al. (2009). Chromatin Signature Reveals over a Thousand Highly Conserved Large Non-coding RNAs in Mammals. Nature 458 (7235), 223–227. doi:10.1038/nature07672

Han, J. Y., Guo, S., Wei, N., Xue, R., Li, W., Dong, G., et al. (2020). cIR-7 Promotes the Proliferation and Migration of Papillary Thyroid Cancer by Negatively Regulating the miR-7/epidermal Growth Factor Receptor axis. Biomed. Res. Int. 2020, 9875636. doi:10.1155/2020/9875636

Fang, C., Xu, L., He, W., Dai, J., and Sun, F. (2019). Long Noncoding RNA DLX6-AS1 Promotes Cell Growth and Invasiveness in Bladder Cancer via Modulating the miR-223-Hsp90b1 axis. Cell Cycle 18 (23), 3288–3299. doi:10.1080/15384101.2019.1673633
Zhang, N., Meng, X., Mei, L., Zhao, C., and Chen, W. (2019). LncRNA DLX6-AS1 Promotes Tumor Proliferation and Metastasis in Osteosarcoma through Modulating miR-641/HOXA9 Signaling Pathway. *J. Cel Biochem* 120 (7), 11478–11489. doi:10.1002/jcb.29426

Zhang, R. M., Tang, T., Yu, H. M., and Yao, X. D. (2018). LncRNA DLX6-AS1/miR-129-5p/DLK1 axis Aggravates Stemness of Osteosarcoma through Wnt Signaling. *Biochem. Biophys. Res. Commun.* 507 (1), 260–266. doi:10.1016/j.bbrc.2018.11.019

Zhang, X., Guo, H., Bao, Y., Yu, H., Xie, D., and Wang, X. (2019). Exosomal Long Non-coding RNA DLX6-AS1 as a Potential Diagnostic Biomarker for Non-small Cell Lung Cancer. *Oncol. Lett.* 18 (5), 5197–5204. doi:10.3892/ol.2019.10892

Zhao, H., and Xu, Q. (2020). Long Non-coding RNA DLX6-AS1 Mediates Proliferation, Invasion and Apoptosis of Endometrial Cancer Cells by Recruiting p300/E2F1 in DLX6 Promoter Region. *J. Cel. Mol. Med.* 24 (21), 12572–12584. doi:10.1111/jcmm.15810

Zhao, J., and Liu, H. R. (2019). Down-regulation of Long Noncoding RNA DLX6-AS1 Defines Good Prognosis and Inhibits Proliferation and Metastasis in Human Epithelial Ovarian Cancer Cells via Notch Signaling Pathway. *Eur. Rev. Med. Pharmacol. Sci.* 23 (8), 3243–3252. doi:10.26355/eurrev_201904_17684

Zhao, P., Guan, H., Dai, Z., Ma, Y., Zhao, Y., and Liu, D. (2019). Long Noncoding RNA DLX6-AS1 Promotes Breast Cancer Progression via miR-505-3p/RUNX2 axis. *Eur. J. Pharmacol.* 865, 172778. doi:10.1016/j.ejphar.2019.172778

Zhao, Y.-H., Wang, Z., Zhang, N., Cui, T., and Zhang, Y.-H. (2020). Effect of ciRS-7 Expression on clear Cell Renal Cell Carcinoma Progression. *Clin. Med. J.* 133 (17), 2084–2089. doi:10.1097/cm9.0000000000000867

Zhao, Z., Liang, S., and Sun, F. (2020). LncRNA DLX6-AS1 Promotes Malignant Phenotype and Lymph Node Metastasis in Prostate Cancer by Inducing LARGE Methylation. *Front. Oncol.* 10, 1172. doi:10.3389/fonc.2020.01172

Zhu, X., Ma, X., Zhao, S., and Cao, Z. (2021). DLX6-AS1 Accelerates Cell Proliferation through Regulating miR-497-5p/SNCG Pathway in Prostate Cancer. *Environ. Toxicol.* 36 (3), 308–319. doi:10.1002/tox.23036

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.